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The transient receptor potential vanilloid 1 (TRPV1) participates in synaptic functions
in the brain. In the dentate gyrus, post-synaptic TRPV1 in the granule cell (GC)
dendritic spines mediates a type of long-term depression (LTD) of the excitatory
medial perforant path (MPP) synapses independent of pre-synaptic cannabinoid CB1
receptors. As CB1 receptors also mediate LTD at these synapses, both CB1 and
TRPV1 might be influencing the activity of each other acting from opposite synaptic
sites. We tested this hypothesis in the MPP–GC synapses of mice lacking TRPV1
(TRPV1-/-). Unlike wild-type (WT) mice, low-frequency stimulation (10min at 10Hz)
of TRPV1-/- MPP fibers elicited a form of long-term potentiation (LTP) that was
dependent on (1) CB1 receptors, (2) the endocannabinoid 2-arachidonoylglycerol
(2-AG), (3) rearrangement of actin filaments, and (4) nitric oxide signaling. These
functional changes were associated with an increase in the maximum binding
efficacy of guanosine-5′-O-(3-[35S]thiotriphosphate) ([35S]GTPγS) stimulated by the CB1
receptor agonist CP 55,940, and a significant decrease in receptor basal activation
in the TRPV1-/- hippocampus. Finally, TRPV1-/- hippocampal synaptosomes showed
an augmented level of the guanine nucleotide-binding (G) Gαi1, Gαi2, and Gαi3 protein
alpha subunits. Altogether, the lack of TRPV1 modifies CB1 receptor signaling in the
dentate gyrus and causes the shift from CB1 receptor-mediated LTD to LTP at the
MPP–GC synapses.
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INTRODUCTION
Cannabinoid functions in the brain are typically associated
with the activation of cannabinoid CB1 receptors (Kano et al.,
2009; Katona and Freund, 2012; Pertwee, 2015; Lu and Mackie,
2016). Additionally, endogenous, plant-derived, and synthetic
cannabinoids could have other molecular targets. In particular,
several cannabinoid effects depend on the activation of members
of the transient receptor potential (TRP) channel family (De
Petrocellis et al., 2011; Morales and Reggio, 2017; Muller et al.,
2019). For example, the synthetic cannabinoid WIN 55,212-
2 exerts analgesic effects by acting on the transient receptor
potential vanilloid 1 (TRPV1) (Jeske et al., 2006; Patwardhan
et al., 2006; Ruparel et al., 2011).
The TRPV1 receptors are expressed in different brain regions
and cell types (Tóth et al., 2005; Cristino et al., 2006; Cavanaugh
et al., 2011). Particularly in the hippocampus, functional TRPV1
receptors in the long term depress excitatory pyramidal cell–
interneuron synapses (Gibson et al., 2008), and pre-synaptic
TRPV1 facilitates the release of glutamate at the excitatory
synaptic terminals in the CA1 hippocampus (Bialecki et al.,
2020). TRPV1 also localizes to the post-synaptic sites of
excitatory and inhibitory synaptic terminals in the molecular
layer (ML) of the dentate gyrus where it plays a key role in
the synaptic transmission and plasticity (Chávez et al., 2010;
Chavez et al., 2014; Canduela et al., 2015; Puente et al., 2015).
Thereby, like in other brain regions (Lafourcade et al., 2007;
Grueter et al., 2010; Puente et al., 2011), long-term depression
(LTD) at medial perforant path (MPP) synapses is mediated
by post-synaptic TRPV1 activity (Chávez et al., 2010) and CB1
receptor signaling (Peñasco et al., 2019; Fontaine et al., 2020).
Conversely, high-frequency stimulation (HFS) of the lateral
perforant path (LPP) triggers a CB1 receptor-dependent long-
term potentiation (LTP) that requires post-synaptic N-methyl-
D-aspartate (NMDA) receptors, metabotropic glutamate receptor
5 (mGluR5), and mobilization of the endocannabinoid 2-
arachidonoylglycerol (2-AG) (Wang et al., 2016). Anatomically,
the constitutive absence of TRPV1 in mice alters the principal
degrading enzymes of 2-AG and anandamide (AEA, the other
main endocannabinoid), as well as modifies CB1 receptors
Abbreviations: ACSF, Artificial cerebrospinal fluid; AEA, Arachidonoyl-
ethanolamine or anandamide; AMPA, D-Amino-3-hydroxy-5-methyl-4-
isoxazole-propionic acid; BSA, Bovine serum albumin; CA1, Region 1 of Cornu
ammonis; CB1 receptor, Type I cannabinoid receptor; CRIP1a, Cannabinoid
receptor-associated protein 1a; DAGL, Diacylglycerol lipase; DMSO, Dimethyl
sulfoxide; eCB, Endocannabinoid; ECS, Endocannabinoid system; eCB-eLTD,
Endocannabinoid-mediated long-term depression of excitation; eLTD, Long-
term depression of excitation; FAAH, Fatty acid amide hydrolase; fEPSP,
Field excitatory post-synaptic potential; FIJI, Fiji is just IMAGE J; LFS,
Low-frequency stimulation; LPP, Lateral perforant path; LTD, Long-term
depression; LTP, Long-term potentiation; MAGL, Monoacylglycerol lipase;
mGluR, Metabotropic glutamate receptors; mGluR5, Metabotropic glutamate
receptor 5; ML, Molecular layer; MPP, Medial perforant pathway; NMDAR,
N-methyl-D-aspartate receptor; PBS, Phosphate-buffered saline; PP, Perforant
path; PTX, Picrotoxin; PVDF, Polyvinylidene difluoride; RT, Room temperature;
SDS, Sodium dodecyl sulfate; S.E.M., Standard error of the mean; TRP, Transient
receptor potential; TRPV1, Transient potential receptors of vanilloid type 1;
TRPV1-/-, TRPV1 knockout; WT, Wild type; 2-AG, 2-Arachidonoyl glycerol;
[35S]GTPγS, Guanosine-5′-O-(3-[35S]thiotriphosphate).
localized to the excitatory and inhibitory terminals in the
outer two-third of ML, the termination zone of the perforant
path (Egaña-Huguet et al., 2021). However, the functional
impact of these adaptive changes on synaptic plasticity is
currently unknown. In this study, we addressed this question by
investigating the effects of the constitutive lack of TRPV1 on the
CB1 receptor-dependent LTD of the excitatory MPP synapses.
MATERIALS AND METHODS
Animals
All protocols were approved by the Committee of Ethics for
Animal Welfare of the University of the Basque Country
(CEEA/M20/2015/105; CEIAB/M30/2015/106) and were in
accordance with the European Communities Council Directive
of September 22, 2010 (2010/63/EU) and Spanish regulations
(Real Decreto 53/2013, BOE 08-02-2013). All efforts were made
to minimize pain and suffering and to reduce the number of
animals used. Seven-/eight-week-old male TRPV1-/- mice (n =
43) and their WT littermates (TRPV1+/+) (n = 21) were used.
The TRPV1-/- mice were derived from heterozygous breeding
pairs as described previously in the study by Egaña-Huguet et al.
(2021). Mice were housed in pairs or groups of maximum three
littermates in standard Plexiglas cages (17 × 14.3 × 36.3 cm),
and before the experiments were conducted, they were allowed
to acclimate to the environment for at least 1 week. They were
maintained at standard conditions with food and tap water ad
libitum throughout all experiments and in a roomwith a constant
temperature (22◦C), and kept in a 12:12 h light/dark cycle with
lights off at 9:00 p.m.
Slice Preparation for Electrophysiology
TRPV1-/- and WT mice were anesthetized by the inhalation of
isoflurane. After decapitation, their brains were rapidly removed
and placed on ice-cold sucrose-based solution that contained
the following components (in mM): 87 NaCl, 75 sucrose, 25
glucose, 7 MgCl2, 2.5 KCl, 0.5 CaCl2, and 1.25 NaH2PO4.
Coronal sections (300µm thick) were cut with a vibratome (Leica
Microsystems S.L.U.), then were recovered at 32–35◦C, and were
superfused (2 mL/min) in the recording chamber with artificial
cerebrospinal fluid (ACSF) containing the following components
(in mM): 130 NaCl, 11 glucose, 1.2 MgCl2, 2.5 KCl, 2.4 CaCl2, 1.2
NaH2PO4, and 23 NaHCO3, equilibrated with 95% O2/5% CO2.
All experiments were carried out at 32–35◦C. The superfusion
medium contained picrotoxin (PTX) (100µM). All drugs were
added to their final concentration in the superfusion medium.
For the extracellular field recordings, a glass recording pipette
was filled with ACSF. The stimulation electrode was placed in the
MPP (middle one-third of the ML) or LPP (outer one-third of
the ML), and the recording pipette was always placed in the inner
one-third of the dentate ML (mossy cell fiber layer).
A low-frequency stimulation (LFS, 10min at 10Hz) was
applied to induce endocannabinoid-dependent excitatory LTD
(eCB-eLTD) of glutamatergic inputs following the recording of
a steady baseline in the presence of drugs (Puente et al., 2011;
Peñasco et al., 2019). The fEPSP slope, area, and amplitude
were measured (graphs depict the area). MPP stimulation was
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confirmed by the group II mGluRs agonist LY354740. Consistent
with previous reports (Macek et al., 1996; Chiu and Castillo,
2008; Chávez et al., 2010), 1µM of LY354740 strongly reduced
MPP-fEPSPs by 59.60± 1.451% 10min after the drug application
(n = 4, ∗∗p < 0.002) (data not shown). The magnitude of
the eCB-eLTD after the LFS stimulation was calculated as
the percentage change between baseline (averaged excitatory
responses for 10min before LFS) and last 10min of stable
responses, normally at 30min after the end of the LFS. The slices
used for each experimental condition (n) were obtained from at
least three mice.
Extracellular Field Recordings
To evoke field excitatory post-synaptic potential responses
(fEPSPs), repetitive control stimuli were delivered at 0.1Hz
(Stimulus Isolator ISU 165, Cibertec, Spain; controlled
by a Master-8, A.M.P.I.). An Axopatch-200B (Axon
Instruments/Molecular Devices, Union City, CA, United States)
was used to record the data filtered at 1–2 kHz, digitized at 5 kHz
on a DigiData 1440A interface (Axon Instruments/Molecular
Devices, Union City, CA, United States). Data were collected on
a PC using Clampex 10.0 (Axon Instruments/Molecular Devices,
Union City, CA, United States) and analyzed using Clampfit
10.0 (Axon Instruments/Molecular Devices, Union City, CA,
United States). At the start of each experiment, an input–output
curve was constructed. A stimulation intensity was selected for
baseline measurements that yielded between 40 and 60% of the
maximal amplitude response.
Hippocampal Membrane Preparation
Synaptosomes were prepared as previously described by the
study by Garro et al. (2001). TRPV1-/- and WT mice (n =
7 each) were anesthetized with isoflurane and decapitated; the
brains were removed and placed on ice-cold 0.32M sucrose,
pH 7.4, containing 80 and 20mM NaH2PO4 (sucrose phosphate
buffer) with protease inhibitors (iodoacetamide 50µM, PMSF
1mM). The hippocampal tissue was minced and homogenized
in 10 volumes of sucrose/phosphate buffer using a motor-driven
Potter Teflon glass homogenizer (motor speed 800 rpm; 10
up and down strokes; mortar cooled in an ice-water mixture
throughout). The homogenate was centrifuged at 1,000 × g
for 10min, and the obtained pellet (P1) was re-suspended and
pelleted. The supernatants (S1 + S1′) were pelleted at 15,000
× g (P2) and re-suspended in the homogenization buffer to a
final volume of 16mL. The suspension was layered directly onto
the tubes containing 8ml of 1.2M sucrose/phosphate buffer and
centrifuged at 180,000 × g for 20min. The material retained
at the gradient interface was carefully collected with a Pasteur
pipette and diluted with the ice-cold 0.32M sucrose/phosphate
buffer to a final volume of 16ml. The diluted suspension was
then layered onto 8ml of 0.8M sucrose/phosphate buffer and
centrifuged as described above. The obtained pellet was re-
suspended in the ice-cold phosphate buffer, pH 7.5, and aliquoted
in microcentrifuge tubes. Aliquots were then centrifuged at
40,000 × g for 30min, the supernatants were aspirated, and the
pellets corresponding to the nerve terminal membranes were
stored at −80◦C. The protein content was determined using the
Bio-Rad dye reagent with bovine γ-globulin as a standard.
Western Blotting of Hippocampal
Synaptosomes
Hippocampal extracts from TRPV1-/- and WT were boiled
in urea-denaturing buffer [20mM Tris–HCl, pH 8.0, 12%
glycerol, 12% urea, 5% dithiothreitol, 2% sodium dodecyl
sulfate (SDS), and 0.01% bromophenol blue] for 5min.
Increasing concentrations (2, 4, 8, 12, 16, and 20 µg/µL) of
denatured proteins were resolved by electrophoresis on SDS–
polyacrylamide (SDS–PAGE) gels (10%) using the Mini Protean
II gel apparatus (Bio-Rad, Hercules, CA, United States). Proteins
were transferred to polyvinylidene fluoride (PVDF) membranes
(Amersham Biosciences, Buckinghamshire, United Kingdom)
using the Mini TransBlot transfer unit (Bio-Rad, Hercules, CA,
United States) at 90V constant voltage for 1 h at 4◦C. Blots
were blocked in 5% non-fat dry milk/PBS containing 0.5%
BSA and 0.2% Tween for 1 h, and incubated overnight at 4◦C
with anti-Gαo (0.04 ng/µL: Santa Cruz Biotechnology; rabbit
polyclonal: K-20; AB_2314438), anti-Gαi1 (0.2 ng/µL; Santa
Cruz Biotechnology; rabbit polyclonal: sc-391, AB_2247692),
anti-Gαi2 (0.2 ng/µL; Santa Cruz Biotechnology; rabbit
polyclonal: sc-7276, AB_2111472), and anti-Gαi3 antibodies
(4 pg/µl; Santa Cruz Biotechnology; rabbit polyclonal: sc-
262, AB_2279066). Blots were washed and incubated with
horseradish peroxidase (HRP)-conjugated secondary antibody
goat anti-rabbit IgG HRP (1 ng/mL; Cell Signalling Technology;
7074; RRID: AB_2099233) diluted to 1:10,000 in the blocking
buffer for 2 h at room temperature. Immunoreactive bands were
incubated with the ECL system according to the manufacturer’s
instructions and detected in an Autochemi-UVP Bioimaging
System. Then, the bands were quantified with Image-J (FIJI)
(NIH, United States; RRID: SCR_003070), and the differences
between the relative expressions of proteins were analyzed by
the regression line slope comparison method using a statistical
software package (see Supplementary Material). The protein
loading was determined by the Coomassie Brilliant Blue gel
staining method (see Supplementary Material) (GraphPad
Prism, GraphPad Software Inc, San Diego, United States).
[35S]GTPγS Binding Assays
Hippocampal extracts (25 µg protein) were thawed and
incubated at 30◦C for 2 h in [35S]GTPγS-incubation buffer
(0.5 nM [35S]GTPγS, 1mM EGTA, 3mMMgCl2, 100mM NaCl,
0.2mM DTT, 50µM GDP, and 50mM Tris–HCl, pH 7.4).
The CB1 receptor agonist CP 55,940 (10
−11-10−5 M, eight
concentrations) was added to determine the receptor-stimulated
[35S]GTPγS binding. Non-specific binding was defined in
the presence of 10µM unlabeled GTPγS. Basal binding was
assumed to be the specific [35S]GTPγS binding in the absence
of an agonist. The reactions were terminated by the rapid
vacuum and filtration through Whatman GF/C glass fiber filters,
and the remaining bound radioactivity was measured by the
liquid scintillation spectrophotometry. For the analysis of data,
individual CP 55,940 concentration–response curves were fitted
by the non-linear regression method to the four-parameter Hill
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FIGURE 1 | Excitatory synaptic transmission at the medial perforant path (MPP) synapses in WT and TRPV1-/- mice. For representation, experiments were
normalized to its baseline. (A) Time-course plot of average fEPSP areas is represented. Black arrow indicates the time point when the drug was applied. CP 55,940
[10µM] reduces significantly the excitatory synaptic transmission in WT, but not in TRPV1-/-. (B) Representative histograms of the last 10min of fEPSP after CP
55,940 application in WT (Mann–Whitney test. ***p < 0.001) and TRPV1-/- (Mann–Whitney test. p > 0.05) mice. All data are expressed as mean ± SEM.
equation, using GraphPad Prism (GraphPad Prism, GraphPad
Software Inc, San Diego, United States):
E = Basal+ Emax − Basal/1+ 10(LogEC50 − Log[A])nH
where E denotes the effect, log [A] the logarithm of the
concentration of agonist, nH the midpoint slope, LogEC50
the logarithm of the midpoint location parameter, and Emax
and Basal the upper and lower asymptotes, respectively.
When required, simultaneous model fitting with parameter
sharing across the datasets was performed using GraphPad
Prism (GraphPad Prism, GraphPad Software Inc, San Diego,
United States). The EC50 values were transformed into
pEC50 (–LogEC50) as EC50, and affinity constants obtained
experimentally are log-normally distributed. Therefore, statistical
analysis was performed accordingly (Christopoulos, 1998).
Drugs and Chemicals
All drugs for performing electrophysiological studies were
dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich) and
were added at the final concentration to the superfusionmedium.
CP 55,940, AMG9810, LY354740, AM251, URB597, JZL 184,
tetrahydrolipstatin (THL), latrunculin A (LAT-A), and PTX were
purchased from Tocris BioScience (Bristol, United Kingdom).
S-Nitroso-N-acetylpenicillamine (SNAP) was purchased from
Abcam (Cambridge, MA). All drugs were perfused at least 20min
before the LFS protocol apart from JZL 184. JZL 184 was
preincubated at least 1 h before LFS protocol.
Experimental Design and Statistical
Analysis
All values are given asmean± SEMwith p-values and sample size
(n). Shapiro–Wilk and Kolmogorov–Smirnov tests were used to
confirm the normality of the data. Statistical significance between
groups was tested using parametric or non-parametric two-tailed
Student’s t-test as required. The significance level was set at p <
0.05 for all comparisons. All statistical tests were performed with
GraphPad Prism (GraphPad Prism, GraphPad Software Inc, San
Diego, United States).
RESULTS
Synaptic Potentiation of the MPP
Synapses in TRPV1-/- Mice
As expected inWT littermates (Peñasco et al., 2019), fEPSPs were
significantly reduced after applying the CB1 receptor agonist CP
55,940 [(10µM); 75.31 ± 6.496%; ∗∗∗p = 0.0003 vs. baseline]
(Figures 1A,B). In contrast, CP 55,940 did not change fEPSPs
in TRPV1-/- mice [(10µM); 103 ± 8.978%; ns; p = 0.7748 vs.
baseline] (Figures 1A,B).
The fEPSPs were significantly reduced after low LFS (10min
at 10Hz) of MPP in WT littermates (80.21 ± 6.497%; ∗∗p
= 0.0021 vs. baseline) (Figures 2A,C). However, a significant
fEPSP potentiation (MPP-LTP) was observed in TRPV1-/- mice
after the similar stimulation pattern (135 ± 7.119%; ∗∗∗∗p <
0.0001 vs. baseline) (Figures 2A,D). This LTP was significantly
reversed by the CB1 receptor antagonist AM251, indicating
that CB1 receptors were involved [(4µM); 95.37 ± 8.263%;
ns; p > 0.9999 vs. baseline; ∗∗p = 0.0034 vs. the fEPSP
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FIGURE 2 | (A) Low-frequency stimulation (LFS) triggers long-term depression (LTD) at the medial perforant path (MPP) synapses in WT (white circles) and long-term
potentiation (LTP) in TRPV1-/- (black circles). (B) Similar stimulation elicits the long-term potentiation at the lateral perforant path (LPP) in WT (white circles) and
TRPV1-/- (black circles). For representation, each experiment was normalized to its baseline. The average of the fEPSP areas is shown. Arrows point to LFS
application (10min, 10Hz). Representative histograms of fEPSP (last 10min) after LFS at MPP in: (C) WT (Mann–Whitney test. **p < 0.005 vs. baseline), (D) TRPV1-/-
(Mann–Whitney test. ****p < 0.0001 vs. baseline), and after LFS at LPP in (E) WT (unpaired t-test. **p < 0.005 vs. baseline), and (F) TRPV1-/- (Mann–Whitney test.
**p < 0.005 vs. baseline). All data are expressed as mean ± SEM.
potentiation obtained in TRPV1-/-] (Figures 3A,B, respectively).
Moreover, bath application of the TRPV1 antagonist AMG9810
significantly potentiated fEPSPs at the MPP synapses of WT
[(3µM); 116.8 ± 5.957%; ∗p = 0.0185 vs. baseline] (Figure 3A);
however, it was not as robust as in TRPV1-/- [(3µM): 116.8 ±
5.957%; ns; p = 0.0638 vs. potentiation value from TRPV1-/-]
(Figure 3B). In addition, the potentiation obtained by blocking
TRPV1 receptors was also reduced by AM251 [(4µM); 100.6
± 4.653%; ns; p = 0.9656 vs. baseline] (Figure 3A) to a
similar extent to the reduction caused by AM251 in TRPV1-
/- [WT mice with AMG9810 (3µM) + AM251 (4µM): 100.6
± 4.653%; ∗p = 0.0413 vs. the potentiation value from WT
+ AMG9810] (Figure 3B). Together, these data suggest that
TRPV1 blockade can shift the CB1 receptor-dependent LTD
to LTP elicited by LFS of MPP. In contrast to the results
obtained in the MPP, the application of the 10Hz stimulation
at LPP synapses did not induce a depression in the WT
littermates; rather, it produced a significant potentiation (142
± 13.44 %: ∗∗p = 0.0068 vs. baseline) (Figures 2B,E), as
previously described in the study by Wang et al. (2016).
This LPP-LTP was maintained in the LPP synapses of
TRPV1-/- mice (142.9 ± 8.314 %; ∗∗p = 0.0022 vs. baseline)
(Figures 2B,F).
Endocannabinoid-Mediated Synaptic
Potentiation of the MPP Synapses in
TRPV1-/- Mice
The MPP-LTP in TRPV1-/- mice was blocked by 1-h pre-
incubation with the monoacylglycerol lipase (MAGL) inhibitor
JZL 184 [(50µM); 104.9 ± 5.317%; ns; p = 0.1304 vs. baseline;
∗∗p = 0.0058 vs. the potentiation value from TRPV1-/-]
(Figures 3C,D, respectively) and significantly reduced by
THL, a diacylglycerol lipase (DAGL) inhibitor [(10µM);
112.9 ± 5.295%; ∗∗p = 0.0040 vs. baseline; ∗p = 0.0273
vs. the potentiation value from TRPV1-/-] (Figures 3C,D,
respectively). However, the fatty acid amide hydrolase
(FAAH) inhibitor URB597 was ineffective at inhibiting
MPP-LTP in TRPV1-/- [(2µM); 135.5 ± 13.65%; ns; p
= 0.1431 vs. baseline; ns; p = 0.9989 vs. the potentiation
value from TRPV1-/-] (Figures 3C,D, respectively). These
data suggest that CB1 receptors and 2-AG (but no AEA)
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FIGURE 3 | (A) Medial perforant path long-term potentiation (MPP-LTP) in TRPV1-/- is CB1 receptor-dependent (Mann–Whitney test. p > 0.05 vs. baseline; white
squares). The TRPV1 antagonist AMG9810 (3µM) triggers MPP-LTP in WT (Mann–Whitney test. *p < 0.05 vs. baseline; light gray circles) that is also CB1
receptor-dependent (Mann–Whitney test. p > 0.05 vs. baseline; dark gray hexagons). (B) Representative histograms of fEPSP (last 10min) after LFS at MPP in
(Continued)
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FIGURE 3 | different conditions: TRPV1-/- mice (black bar); TRPV1-/- + AM251 [4µM] (white bar); WT + AMG9810 [3µM] (light gray bar); and WT + AMG9810
[3µM] + AM251 [4µM] (dark gray bar). Statistical analysis of last 10min of fEPSP after LFS in the MPP from different conditions: TRPV1-/- vs. TRPV1-/- + AM251
[4µM] (Mann–Whitney test. **p < 0.005); TRPV1-/- vs. WT + AMG9810 [3µM] (Mann–Whitney test. p > 0.05) and WT + AMG9810 vs. WT + AMG9810 [3µM] +
AM251 [4µM] mice (unpaired t-test. *p < 0.05). (C) Increase (Mann–Whitney test. p > 0.05 vs. baseline; white circles) and decrease (Mann–Whitney test. **p < 0.005
vs. baseline; light gray diamonds) in 2-AG abolish MPP-LTP in TRPV1-/-, while AEA increase (Mann–Whitney test. p > 0.05 vs. baseline; dark gray squares) has no
effect. (D) Representative histogram of fEPSP (last 10min) after LFS at MPP in TRPV1-/- (black bar) in the presence of JZL 184 [50µM; >1 h] (white bar), THL [10µM]
(light gray bar), and URB597 [2µM] (dark gray bar). Statistical analysis of last 10 mins fEPSP after LFS in the MPP of TRPV1-/- mice in the presence of different drugs:
TRPV1-/- vs. TRPV1-/- + JZL 184 (unpaired t-test. **p < 0.005), TRPV1-/- vs. TRPV1-/- + THL (unpaired t-test. *p < 0.05), and TRPV1-/- vs. TRPV1-/- + URB597
(unpaired t-test. p > 0.05). (E) SNAP blocks (Mann–Whitney test. p > 0.05 vs. baseline; white diamonds) and LAT-A reduce MPP-LTP in TRPV1-/- (Mann–Whitney
test. *p < 0.05 vs. baseline; light gray circles) but not LTP induced by AMG9810 in WT (Mann–Whitney test. p > 0.05 vs. baseline; dark gray hexagons). (F)
Representative histogram of the last 10min of fEPSP after LFS in different conditions: SNAP in TRPV1-/- [100µM] (white bar); LAT-A in TRPV1-/- (light gray bar), and
LAT-A in WT + AMG9810 mice (dark gray bar). Statistical analysis of last 10min of fEPSP after LFS in the MPP of different conditions: TRPV1-/- vs. TRPV1-/- + SNAP
(Mann–Whitney test. ***p < 0.001); TRPV1-/- vs. TRPV1-/- + LAT-A (unpaired t-test. *p < 0.05); and WT + AMG9810 vs. WT + AMG9810 + LAT-A (unpaired t-test.
p > 0.05). All data are expressed as mean ± SEM. (A,C,E) For representation, each experiment was normalized to its baseline. The average of the fEPSP areas is
shown. Arrows point to LFS application (10min, 10Hz).
are required for MPP-LTP in TRPV1-/- mice. Furthermore,
the nitric oxide (NO) donor SNAP blocked MPP-LTP
in TRPV1-/- [(0.1mM); 91.02 ± 5.804%; ∗p = 0.0232 vs.
baseline; ∗∗∗p = 0.0003 vs. potentiation value from TRPV1-/-]
(Figures 3E,F, respectively).
Polymerization of actin filaments was shown to be
necessary for the LTP driven by CB1 receptors in the LPP
synapses (Wang et al., 2016, 2018). In TRPV1-/- mice,
the actin polymerization inhibitor LAT-A significantly
reduced MPP-LTP [(0.5mM); 114.6 ± 5.78%; ∗p =
0.0104 vs. baseline; ∗p = 0.0348 vs. potentiation value
from TRPV1-/-] (Figures 3E,F, respectively). LAT-A,
in turn, did not modify the LTP elicited by AMG9810
in WT (120.9 ± 9.248 %; ns; p = 0.1431 vs. baseline;
ns; p = 0.2173 vs. potentiation value from TRPV1-/-)
(Figures 3E,F, respectively).
Expression of Gαi/o Subunits and CP
55,940 Stimulated [35S]GTPγS Binding in
Synaptosomal Fractions From TRPV1-/-
and WT Hippocampi
There were no significant differences in the Gαo subunit
expressed in the synaptosomal fractions of TRPV1-
/- and WT (TRPV1-/-: 6.25 ± 0.1598 vs. WT: 6.32 ±
0.1582; ns; p = 0.8633) (Figures 4A,B). However, Gαi1
(TRPV1-/-: 11.20 ± 0.0892 vs. WT: 7.85 ± 0.1273; ∗∗p =
0.0056), Gαi2 (TRPV1-/-: 8.399 ± 0.1191 vs. WT: 6.399
± 0.1563; ∗∗p = 0.0065), and Gαi3 subunits (TRPV1-/-
: 8.142 ± 0.1228 vs. WT: 6.646 ± 0.1505; ∗∗p = 0.015)
(Figure 4B) were significantly increased in TRPV1-/-
mouse hippocampus.
The CB1 receptor agonist CP 55,940 stimulated [
35S]GTPγS
binding in a concentration-dependent manner (Figure 4C). The
maximum efficacy (Emax) significantly increased in TRPV1-
/- (193.70 ± 12.21% of the basal activation) relative to WT
(maximum efficacy: 176.20 ± 9.73% of the basal activation;
∗p < 0.05) (Figure 4C), with no changes in potency (pEC50
in TRPV1-/-: 6.58 ± 0.01 vs. WT: 6.47 ± 0.14; ns; p =
0.5139) (Figure 4C). Also, a significant decrease in the basal
activation of the receptor was detected (TRPV1-/-: 83.45 ±
2.88% vs. WT: 100 ± 1.24%; ∗∗p = 0.0019) (Figure 4D).
Agonist’s maximal efficacy, which is defined as the maximal
difference between specific [35S]GTPyS binding in the presence
and absence of agonist, was calculated as the percentage of
basal activation. However, if the data were not normalized
to their corresponding basal values, Emax differences were
not statistically significant (see captions and the inset of
Figure 4C).
DISCUSSION
The aim of this investigation was to study the impact of the
genetic deletion of TRPV1 on the CB1 receptor functionality and
synaptic plasticity in the hippocampal dentate gyrus. Particularly,
the TRPV1-/- mice have (1) an increase in the CB1 receptor
coupling efficacy and (2) a shift from CB1 receptor-dependent
LTD to LTP at the MPP–granule cell (GC) synapses.
We observed an increase in the CB1 receptor-related Gαi1,
Gαi2, and Gαi3 subunits in synaptosomal fractions of TRPV1-/-.
Furthermore, CB1 receptor functionality was altered in TRPV1-
/- as the receptor showed a significant higher maximum
coupling efficacy and a lower basal activation. These changes
should be interpreted in the context of the decrease in CB1
receptors in the synaptosomal fractions (Egaña-Huguet et al.,
2021). In fact, taking into account that [35S]GTPγS binding
assays reflect a primary response of the system, the decrease
in CB1 receptors could be expected to produce a decrease
in maximal responses. However, the achievement of similar
maximal responses in TRPV1-/- synaptosomal fractions together
with a decrease in basal levels reveals an increase in the
coupling efficacy induced by the agonist. Similarly, the decrease
in the constitutive activation of G-proteins could be linked
to the decrease in CB1 receptor expression. Actually, the CB1
receptor-induced suppression of the fEPSP revealed at the
MPP–GC synapses (Peñasco et al., 2019) was not observed in
TRPV1-/-. However, although CB1 receptors located on the
glutamatergic synapses are tightly coupled to G protein signaling
(Steindel et al., 2013), basal activation in the hippocampus could
not only correspond to CB1 receptors as Gi/o proteins are
also coupled to other metabotropic receptors besides the CB1
receptor (Conn and Pin, 1997). In addition, a drastic increase
in the cannabinoid receptor-interacting protein 1a (CRIP1a)
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FIGURE 4 | Molecular changes in Gαo and Gαi subunits in TRPV1-/-. (A,B) Immunoblot and relative expression of Gαo, Gαi1, Gαi2, and Gαi3 proteins in synaptosomal
extracts with increasing protein concentrations (4, 8, 12, and 16 µg/µl) from WT and TRPV1-/- mice hippocampi. p > 0.05; *p < 0.05; **p < 0.005. Data are
expressed as mean ± SEM. (C) CP 55,940-stimulated [35S]GTPγS binding assay in the hippocampal synaptosome fractions from WT and TRPV1-/-. Concentration
curves were constructed using mean values ± SEM from four different experiments performed in triplicate. Paired t-test; *p < 0.05. Inset: CP 55,940
concentration–response curves are expressed in cpm (counts per minute) to show non-normalized basal (WT: 22.179 ± 2.844 cpm vs. TRPV1-/-: 18.715 ± 2.816.
Paired t-test; *p < 0.05) and Emax values (WT: 39.079 ± 2.844 cpm vs. TRPV1-/-: 36.251 ± 2.285 cpm. Paired t-test; ns; p > 0.05). (D) Bar graph representing the
relative percentage of [35S]GTPγS basal binding levels in WT and TRPV1-/-. Unpaired t-test; **p < 0.005. Data are represented as mean ± SEM.
was detected previously in TRPV1-/- hippocampus (Egaña-
Huguet et al., 2021). CRIP1a reduces the agonist-stimulated CB1
receptor internalization and attenuates CB1 receptor signaling,
thus increasing neurotransmitter release (Booth et al., 2019;
Oliver et al., 2020). Furthermore, CRIP1a overexpression in
N18TG2 cells produces a robust stimulation of [35S]GTPγS
binding toGαi1 andGαi2 subunits (Blume et al., 2015). Therefore,
taking into account that TRPV1-/- courses with an increased Gαi
expression in the hippocampus, the potentiation observed in the
[35S]GTPγS binding after CP 55,940 stimulation might be related
to the CRIP1a rise (Blume et al., 2015; Booth et al., 2019; Oliver
et al., 2020).
The present results also show a CB1 receptor-dependent shift
to MPP-LTP in TRPV1-/- (Figure 5) after applying the LFS that
elicits MPP-LTD under normal conditions (Peñasco et al., 2019;
Fontaine et al., 2020). Interestingly, this type of potentiation is
independent of NMDAR signaling, although eCB-eLTD requires
NMDA receptor activation at other synapses (Sjöström et al.,
2003; Bender et al., 2006; Lutzu and Castillo, 2021). These results
highlight the importance of the crosstalk between CB1 and
TRPV1 signaling in this form of synaptic plasticity.
The MPP-LTP in TRPV1-/- was abolished in the presence of
DAGL or MAGL inhibitors. This suggests that 2-AG regulation
may be a limiting factor for this kind of synaptic plasticity.
Consequently, as observed for the eCB-eLTD at the MPP–GC
synapses (Peñasco et al., 2019), CB1 receptor desensitization
caused by high 2-AG concentration (Chanda et al., 2010;
Schlosburg et al., 2010) could be responsible for the MPP-LTP
blockade. Altogether, our findings suggest that 2-AG acting on
CB1 receptors mediates MPP-LTD and MPP-LTP in WT and
TRPV1-/-, respectively, in which levels and timing of 2-AG
availability might be playing a role in this switch from LTD to
LTP (Cui et al., 2018).
The MPP-LTP in TRPV1-/- might stand on the ability of
LFS (1Hz) of the MPP–GC synapses to induce CB1 receptor-
independent LTD that relies on AEA, post-synaptic TRPV1,
and AMPA receptor internalization (Chávez et al., 2010).
However, MPP-LTP in TRPV1-/- was unaffected by the FAAH
inhibitor URB597 (2µM), indicating that AEA would not be
involved. Actually, the conspicuous TRPV1 localization in the
GC dendritic spines post-synaptic to the perforant path synaptic
terminals in the outer two-thirds of the dentate ML (Puente
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FIGURE 5 | Summary of the main findings. The absence of TRPV1 shifts the cannabinoid CB1 receptor-dependent long-term depression to long-term potentiation at
the excitatory medial perforant path–granule cell synapses in the mouse dentate molecular layer.
et al., 2015) endorses TRPV1-mediated synaptic plasticity at
the MPP–GC synapses. The differences observed between eCB-
eLTD at the pre-synaptic (Peñasco et al., 2019; Fontaine et al.,
2020) or post-synaptic sites of the MPP–GC synapses (Chávez
et al., 2010) might be regarded as a synergistic effect of CB1
receptors reducing the glutamate release (Peñasco et al., 2019)
and TRPV1 promoting AMPA receptor internalization (Chávez
et al., 2010). Then, the change in CB1 receptors in the absence
of TRPV1 (Egaña-Huguet et al., 2021) could be at the base of
the shift from MPP-LTD to MPP-LTP. However, HFS (100Hz)
of the LPP–GC synapses actually triggers a CB1 receptor-
mediated LTP that requires post-synaptic NMDA receptors and
the production of mGluR5-dependent 2-AG (Wang et al., 2016).
Furthermore, CB1 receptor activation at LPP synaptic terminals
causes the assembly of LAT-sensitive actin filaments resulting
in an increased release of glutamate (Wang et al., 2016, 2018).
In our study, MPP-LTP in TRPV1-/- significantly decreased
in the presence of LAT-A, suggesting a similar mechanism.
Furthermore, our LFS triggered a similar LTP at the LPP–
GC synapses in both WT (Wang et al., 2016, 2018) and
TRPV1-/-, suggesting that the CB1 receptor-mediated LPP-LTP
observed in our model is independent of TRPV1. Moreover,
the MPP-LTP triggered in WT by pharmacological TRPV1
antagonism was significantly reduced by the CB1 receptor
antagonist AM251 but it was unaffected by LAT-A, indicating
that the MPP-LTP upon chemical TRPV1 blockade shares the
CB1 receptor participation but not the intracellular signaling
cascades turned on in the absence of TRPV1 at the MPP–
GC synapses. In this sense, the NO donor SNAP blocked
the MPP-LTP in TRPV1-/-. As TRPV1 is highly permeable
to Ca2+ ions (Caterina et al., 1997; Caterina and Julius,
2001), it is plausible that reduced intracellular calcium caused
by the absence of TRPV1 at the MPP–GC dendritic spine
synapses would damp post-synaptic NO synthase and, therefore,
decrease NO production needed to support pre-synaptic LTD
in the hippocampus (Reyes-Harde et al., 1999). Under normal
conditions, NO activates the pre-synaptic cGMP-dependent
protein kinase (PKG) known to phosphorylate and inactivate
the small GTPase RhoA (Sawada et al., 2001), as well as to
regulate actin cytoskeleton (for review, Francis et al., 2010).
Thus, the lack of NO in the absence of TRPV1 would eventually
lead to the signaling of pre-synaptic molecular pathways that
ultimately would enhance the release of glutamate (Wang et al.,
2018) endorsing MPP-LTP. The possibility of indirect effects on
MPP-LTP by CB1 receptors in other cells like astrocytes should
also be considered, as astroglial CB1 receptors promote the
excitatory LTD by favoring the local glutamate availability (Han
et al., 2012) and endorse LTP at the distant excitatory synapses
(Araque et al., 2017).
Previous studies have shown that TRPV1-/- mice exhibit
learning and conditioned fear deficits as well as anxiety-like
behaviors, which were related to a decrease in excitatory LTP
at CA1 synapses (Marsch et al., 2007). Also, the disappearance
of CB1 receptor-dependent LTD at the MPP synapses in the
adult brain after exposure to intermittent ethanol intake during
the adolescence and the associated recognition memory deficits
were rescued by increasing 2-AG (Peñasco et al., 2020). So the
shift from CB1 receptor-dependent MPP-LTD to MPP-LTP in
TRPV1-/- mice might be affecting memory as the hippocampus
in general (Eichenbaum et al., 2012), and the MPP synapses, in
particular, are involved in spatial memory processing (Fyhn et al.,
2004; Hargreaves et al., 2005).
Altogether, the biochemical and anatomical changes taking
place in the endocannabinoid system of TRPV1-/- mice (Egaña-
Huguet et al., 2021), together with the increase in Gαi1, Gαi2,
and Gαi3 proteins, the low basal CB1 receptor activation, the
high CB1 receptor coupling efficacy, and the shift from MPP-
LTD toMPP-LTP demonstrated in this study support a functional
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crosstalk between TRPV1 and CB1 receptors in the dentate gyrus
(Figure 5).
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